Roche Reports Phase 3 extension Data for Donanemab in Atopic dermatitis

Roche today announced Phase 3 extension results for donanemab in patients with atopic dermatitis. The study demonstrated that donanemab reduces hospitalization rates compared to standard of care or placebo. These results provide important insights into the treatment of atopic dermatitis and support the continued development of donanemab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.